Chemotherapy consisting of cisplatin, epirubicin, and cyclophosphamide in advanced ovarian carcinoma. The Gynecologic Oncology Group of the Comprehensive Cancer Center, Limburg, The Netherlands.

Between January 1985 and May 1988, 87 patients with stage III-IV ovarian carcinoma were entered in a study assessing chemotherapy consisting of cyclophosphamide, 500 mg/m2, epirubicin, 75 mg/m2, and cisplatin, 50 mg/m2, intravenously (IV) on day 1, every 4 weeks (CEP-1). The results after a median follow-up of 4 years are presented. The pathologically complete remission rate was 36%. The median survival of all patients was 26 months. For patients with stage III disease debulked to lesions < or = 1.5 cm before the initiation of chemotherapy (n = 35), the median survival was 61+ months. These data are not clearly different from the results of a previous study conducted by our group utilizing CAP-1 chemotherapy.